Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig™, 311C90)

DOI Web Site 被引用文献1件
  • P Rolan
    Head Pain Clinic, Department of Neurology, Manchester Royal Infirmary, Manchester, UK, and Medeval Ltd, University of Manchester, Manchester, UK

書誌事項

公開日
1997-10
権利情報
  • https://journals.sagepub.com/page/policies/text-and-data-mining-license
DOI
  • 10.1177/0333102497017s1804
公開者
SAGE Publications

この論文をさがす

説明

<jats:p> Seven randomized studies in healthy volunteers have investigated interactions between zolmitriptan (Zomig™, formerly 311C90), a 5HT1B/1D agonist for acute migraine therapy, and selected drugs with which there was a possibility of interaction or a likelihood of concurrent use. Co-administration of oral dihydroergotamine, ergotamine, pizotifen, fluoxetine, paracetamol (acetaminophen)/metoclopramide or selegiline had no clinically significant effects on the pharmacokinetics of zolmitriptan or its metabolites, although small changes were observed in some cases. Co-administration of propranolol resulted in a 56% increase in the area under the plasma concentration-time curve (AUC) of zolmitriptan and a 11% decrease in the AUC of the active metabolite 183C91. However, these pharmacokinetic changes are unlikely to be relevant at lower clinical doses. Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91. This suggests that MAO-A is involved in the metabolism of 183C91 and it may be prudent to limit the daily zolmitriptan dose in migraine patients maintained on a MAO-A inhibitor. The clinically insignificant blood pressure increases produced by zolmitriptan, and the tolerability profile of this agent, were unaffected by any of the concomitant medications. Clinically significant interactions between zolmitriptan and commonly co-prescribed antimigraine therapies are unlikely. </jats:p>

収録刊行物

  • Cephalalgia

    Cephalalgia 17 (18_suppl), 21-27, 1997-10

    SAGE Publications

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ